interlukin 6

I came across this abstract a few days ago regarding some Harvard research on Milleniums drug Velcade . They found that when they were able to block the interlukin 6 , their chemo was much more effective against the cancer (multiple myeloma) cell .
That seems to indicate that , even though as far as I know Solbec has not targeted MM , it could be used with other cancer drugs for its ability to shut down the production of IL6 . Increasing its potential market . Also it could be part of the reason SBP002 is so agressive against tumors .

Oncogene (2004) 23, 3597-3602. doi:10.1038/sj.onc.1207458

Original Paper
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

Dharminder Chauhan1, Guilan Li1, Teru Hideshima1, Klaus Podar1, Reshma Shringarpure1, Constantine Mitsiades1, Nikhil Munshi1, P Renee Yew2 and Kenneth C Anderson1

1Department of Medical Oncology, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA

2Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78245-3207, USA

Correspondence to: KC Anderson, E-mail: [email protected]


Abstract

The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma (MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Together, these findings provide evidence that (1) CDC34 expression is associated with growth and survival of MM cells and (2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dex-resistance.